Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs 上半年銷售零收入 歌禮轉攻肥胖藥物
The drug maker failed to generate any revenue in the first half of 2024 even with three major commercialized products in hand 這家制藥公司旗下的三大商業化產品，今年上半年竟然無任何收入進賬。
Bamboo Works (official website) provides news on Chinese companies listed in Hong Kong and the United States, with a strong focus on mid-cap and also pre-IPO companies.